ASCO 2019 - Kantar debates results from the KEYNOTE-062 trial

There were a number of debate-worthy outcomes from the KEYNOTE-062 trial that was presented at ASCO 2019 in Chicago yesterday. The study looked at Merck & Co's Keytruda as a first-line treatment for gastric cancer, and prompted questions about the meaningfulness of non-inferiority. Kantar's Debbie Warner and Michael Gaschler debate the results in the video below. [video width="1280" height="720" mp4="https://pharmaphorum.com/wp-content/uploads/2019/06/Kantar-Vlog-4-03_06_2019-1.mp4"][/video]   Click here to view exclusive live coverage from ASCO 2019.